IP Library Granted Patent US 7,208,493
Granted Patent B2
US 7,208,493 · App. 10/679,209 · Granted Apr 24, 2007

Vasculostatic agents and methods of use thereof

Assignee: TargeGen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,208,493
App. No.
10/679,209
Granted
Apr 24, 2007
Kind
B2
Abstract

Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

Claims (25)

1. A compound of structure (III):

wherein:

each of Z 2 and Z 4 is C, each of Z 1 , Z 3 , Z 5 , and Z 6 is N;

each X is NH 2 ;

each Y is independently selected from a group consisting of —OR d , —NR d 2 , —SR d , and —OPO 3 H 2 , wherein R d is selected from a group consisting of H, lower alkyl, aryl, and —(CH 2 ) 2 NH(CH 2 CH 3 ); or

each Y is independently selected from a group consisting of alkyl, substituted alkyl, aryl, substituted aryl, and halogen, wherein said substituents are selected from a group consisting of halogen, —OR e , —NR e 2 , —SR e , and —P(O)(OH) 2 , wherein R e is selected from a group consisting of —H, lower alkyl, and aryl; or

each Y is independently selected from a group consisting of CH 2 glycinyl, CH 2 NHethoxy, CH 2 NHCH 2 alkyl, CH 2 NHCH 2 t-Bu, CH 2 NHCH 2 aryl, and CH 2 NHCH 2 substituted aryl; or

when n is 2, each Y is taken together to form a fused aromatic ring system; and

m and n are each independently 1 to 4,

wherein when m=n=2, Y is not phenyl or 4-hydroxyphenyl, or tautomers thereof.

2. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier.

3. A compound of claim 1 having the structure:

or pharmaceutically acceptable salts thereof.

4. A compound of claim 1 having the structure:

or pharmaceutically acceptable salts thereof.

5. A compound of claim 1 having the structure:

or pharmaceutically acceptable salts thereof.

6. A compound of claim 1 having the structure:

or pharmaceutically acceptable salts thereof.

7. A compound of claim 1 having any one of the structures:

or pharmaceutically acceptable salts thereof.

8. A compound of claim 1 having the structure:

or pharmaceutically acceptable salts thereof.

9. A compound having the structure:

or pharmaceutically acceptable salts thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2003
From: WRASIDLO, WOLFGANG; DOUKAS, JOHN; ROYSTON, IVOR; NORONHA, GLENN; HOOD, JOHN D.; DNEPROVSKAIA, ELENA; GONG, XIANCHANG; SPLITTGERBER, UTE; ZHAO, NINGNING
To: TARGEGEN, INC.
Reel/Frame 014666/0766 →
Continuity (7)
Provisional Application 6047929500 · Jun 17, 2003
Provisional Application 6046698300 · Apr 30, 2003
Provisional Application 6046381800 · Apr 17, 2003
Provisional Application 6044375200 · Jan 29, 2003
Provisional Application 6044023400 · Jan 14, 2003
Provisional Application 6041598100 · Oct 3, 2002
Related Publication 20040167198A1 · Aug 26, 2004